Ceryvyn Therapeutics Ltd
CKDXF
Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Melbourne, Australia, focused on developing targeted biologic therapies for serious diseases. The company specializes in vascular endothelial growth factor (VEGF) biology and related pathways, applying this expertise to conditions driven by abnormal blood and lymphatic vessel growth and function. Ceryvyn Therapeutics’ current activities center on lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that predominantly affects women, where it is advancing CYV-101, a fusion protein designed to modulate the dysregulated biology underlying the condition. By leveraging prior late-stage clinical experience with this molecule, the company aims to efficiently generate robust clinical data in LAM. Operating within the biotechnology and medical research sector, Ceryvyn Therapeutics serves the broader healthcare market by pursuing therapies intended for high unmet-need indications, with development spanning Australia and the United States. Founded in 1984 and headquartered in Melbourne, it functions as a specialized player in rare disease and VEGF-targeted drug development.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
A$1K
▼ -97.4% YoY
Net Income (TTM)
A$330M
▲ +231.6% YoY
Op. Margin
-1194700.00%
▼ -588435.9pp YoY
ROIC
-80.68%
▲ +183.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-A$12M
▲ +94.9% YoY
Op. Cash Flow (TTM)
-A$12M
▲ +94.9% YoY
Net Debt
-A$30M
Net Cash Position
Cash & Equiv.
A$30M
3Y CAGR: -79.0%
Continue Research
Peers
Biotechnology · Pick stocks to compare with CKDXF
Ceryvyn Therapeutics (CKDXF) in four numbers
Questions about Ceryvyn Therapeutics
Is Ceryvyn Therapeutics (CKDXF) overvalued?
At $0.03, Ceryvyn Therapeutics' price is 2474763% above the $0.00 a share fair value that Intrinsiqq's calculator gets from its revenue. It trades at 0.22 times earnings. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Ceryvyn Therapeutics' fair value?
Intrinsiqq's calculator puts Ceryvyn Therapeutics' fair value at $0.00 a share. It grows revenue per share 0% a year for 5 years, applies an exit P/S of 4.7, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.00. Every input can be changed on the Intrinsic Value tab.
Is Ceryvyn Therapeutics a high-quality business?
Ceryvyn Therapeutics scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 7 checks computed from company filings. Its best check is net debt at -$30M, and its weakest is return on capital at -80.7%. The Quality tab shows every check against its target.
Does Ceryvyn Therapeutics (CKDXF) pay a dividend?
No. Ceryvyn Therapeutics (CKDXF) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 19 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CKDXF
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.